Dermatology Daily Report: 01/23/2024

An integrated safety analysis from the ALLEGRO clinical trial program, involving phase 2a and 2b/3 studies, evaluated ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in patients with alopecia areata (1). The analysis included 1294 patients with a median exposure of 624 days. Ritlecitinib was well tolerated, with 84.5% of patients experiencing adverse events and 4.4% experiencing serious adverse events. The most common adverse events were headache (17.7%), SARS-CoV-2 positive test (15.5%), and nasopharyngitis (12.4%). The trial registries included were ClinicalTrials.gov: NCT02974868, NCT04517864, NCT03732807, and NCT04006457.

Reference

King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska NA, Paul C, Gong Y, Anway SD, Tran H, Wolk R, Zwillich SH, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2024 Jan 23. doi: 10.1007/s40257-024-00846-3. Epub ahead of print. PMID: 38263353.